BETA DRUGS LIMITED Financial Ratios
BETA · Healthcare · Current price ₹2,229.1
P/E ratio
54.5x
P/B ratio
9.1x
ROE
18.8%
ROCE
19.0%
Debt / Equity
0.60
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 54.5x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 9.1x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 18.8% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 19.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.60 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with BETA DRUGS LIMITED's latest numbers.
BETA DRUGS LIMITED profitability
BETA DRUGS LIMITED generates a return on equity of 18.8% and a return on capital employed of 19.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.60 and a P/E of 54.5x, BETA DRUGS LIMITED is moderately leveraged. Our overall business-quality score for the company is 4.4 / 10.
Understand the ratios
More on BETA DRUGS LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.